A Rare De Novo RAI1 Gene Mutation Affecting BDNF-Enhancer-Driven Transcription Activity Associated with Autism and Atypical Smith-Magenis Syndrome Presentation

Clemer Abad, Melissa M. Cook, Lei Cao, Julie R. Jones, Nalini R. Rao, Lynn Dukes‐Rimsky, Rini Pauly, Cindy Skinner, Yunsheng Wang, Feng Luo, R.e. Stevenson, Katherina Walz, Anand SrivastavaBiology 2018 · DOI

TL;DR

This paper identifies a novel de novo mutation in the RAI1 gene in a patient presenting with autism and atypical Smith-Magenis Syndrome (SMS) features. The mutation impairs RAI1's ability to activate transcription of the BDNF gene, suggesting a role for RAI1 in social behavior and potentially contributing to autism spectrum disorder (ASD) and SMS.

What Problem Does This Paper Address?

Smith-Magenis Syndrome (SMS) is a complex neurodevelopmental disorder typically caused by deletions or mutations in the RAI1 gene. While RAI1 is strongly linked to SMS, its precise role in social behavior and its contribution to conditions like Autism Spectrum Disorder (ASD), which can co-occur with SMS, are not fully understood. This paper addresses the question of whether rare RAI1 mutations, beyond the typical deletions, can manifest as primarily autistic symptoms with some SMS-like features, and how these mutations might functionally impact gene regulation related to neurodevelopment.

Methods

The researchers employed a multi-pronged approach:

  • Next-Generation Sequencing (NGS): A diagnostic panel sequencing approach was used to identify genetic variants in the patient, focusing on genes known to be associated with ASD and related syndromes.
  • Sanger Sequencing: Used to confirm the identified variants and to analyze parental DNA for de novo status.
  • Plasmid Constructs and Site-Directed Mutagenesis: Wild-type and mutant RAI1 genes were engineered into plasmids for functional studies.
  • Cell Culture (Neuro-2a cells): These cells were used as a model system for transfecting and studying the behavior of the RAI1 variants.
  • Western Blot and Immunofluorescence: These techniques were used to assess the expression levels and subcellular localization (specifically, nuclear localization) of the wild-type and mutant RAI1 proteins.
  • Reporter Gene Assays: This was a key functional assay. Researchers used a luciferase reporter system driven by a BDNF intronic enhancer sequence. They co-transfected this with plasmids expressing either wild-type or mutant RAI1 to measure the effect of the mutation on transcription activation. A separate assay used a GAL4-BD fusion system to assess general transactivation activity.
  • RNA-Sequencing (RNA-seq): This was used to analyze the global gene expression profile of the patient's lymphoblastoid cells compared to controls, identifying differentially expressed genes that might contribute to the phenotype.
  • Bioinformatic Analyses: Tools like PolyPhen2, SIFT, and CADD were used to predict the pathogenicity of identified variants.

Datasets

  • Patient Genomic DNA: Obtained from the proband and his parents.
  • Control Lymphoblastoid Cell Lines: Nine age-, sex-, and race-matched control individuals were used for RNA-seq analysis.
  • Public Databases: Human Gene Mutation Database, 1000 Genome Project, dbSNP, NHLBI Exome Variant Server, Ensembl variation database, and ExAC dataset were used for variant annotation and frequency checks.
  • Reference Genomes: Human Reference Genome (hg19) was used for RNA-seq alignment.

Key Insights and Ideas

  • RAI1's Role Beyond Classic SMS: The study highlights that RAI1 mutations can present with autism as the primary phenotype, rather than solely classic SMS, suggesting a broader spectrum of RAI1-related neurodevelopmental disorders.
  • BDNF Pathway Disruption: The identified RAI1 mutation significantly impairs the activation of a BDNF enhancer. This is crucial because BDNF is a key neurotrophic factor involved in neuronal development, plasticity, and function, and its dysregulation is implicated in various neurodevelopmental and psychiatric conditions, including autism.
  • Nuclear Localization Intact, but Function Impaired: The mutation did not affect where the RAI1 protein went within the cell (it still localized to the nucleus), but it did impair its ability to do its job there – specifically, to activate transcription. This points to a functional defect rather than a trafficking issue.
  • Complex Genetic Landscape: The patient also had other genetic variants, and RNA-seq revealed altered expression of several genes related to neurobehavioral outcomes. This suggests that while the RAI1 mutation is a strong candidate, the final phenotype might be influenced by a complex interplay of genetic factors.

Key Results

  • A rare, de novo missense mutation, c.3440G > A (p.R1147Q), was identified in the RAI1 gene of the patient.
  • The p.R1147Q mutant RAI1 protein showed no difference in subcellular localization compared to wild-type RAI1.
  • Functional assays revealed that the p.R1147Q mutant RAI1 protein exhibited a significant deficiency (~250-fold induction vs. ~860-fold for WT) in activating transcription from a reporter gene driven by a BDNF intronic enhancer. This impairment was statistically significant (p = 0.01).
  • General transactivation activity using a GAL4-BD system showed a non-significant increase in activity for the mutant protein, suggesting the primary defect is in recognizing specific target enhancers like the BDNF one.
  • RNA-seq analysis identified differentially expressed genes in the patient, including genes like DST (previously linked to autism) and others involved in neurobehavioral abnormalities.

Limitations and Future Work

  • Single Patient Study: The findings are based on a single patient, which limits generalizability. Larger cohorts are needed to confirm the association of this specific mutation or similar ones with autism and atypical SMS.
  • RNA-seq Interpretation: The RNA-seq analysis involved only one patient against nine controls. The authors acknowledge that these findings need further verification in additional cases.
  • EHMT1 Variant: The patient also carried a variant in the EHMT1 gene, which was inherited from his father. While bioinformatic predictions suggested it might be benign, the authors acknowledge it could potentially contribute to the phenotype, especially given recent findings on EHMT1 mosaicism in autism.
  • Future Directions: The authors suggest that RAI1 should be considered a candidate gene for children presenting with autistic manifestations or social behavioral abnormalities. Further studies on larger patient cohorts with similar presentations are warranted to explore the spectrum of RAI1-associated neurodevelopmental disorders and the interplay of other genetic factors. Investigating the downstream effects of BDNF dysregulation due to RAI1 mutations could also be a fruitful area.

Summary updated

Abstract

Deletions and mutations involving the Retinoic Acid Induced 1 (<i>RAI1</i>) gene at 17p11.2 cause Smith-Magenis syndrome (SMS). Here we report a patient with autism as the main clinical presentation, with some SMS-like features and a rare de novo <i>RAI1</i> gene mutation, c.3440G > A (p.R1147Q). We functionally characterized the RAI1 p.R1147Q mutant protein. The mutation, located near the nuclear localization signal, had no effect on the subcellular localization of the mutant protein. However, similar to previously reported RAI1 missense mutations in SMS patients, the RAI1 p.R1147Q mutant protein showed a significant deficiency in activating in vivo transcription of a reporter gene driven by a BDNF (brain-derived neurotrophic factor) intronic enhancer. In addition, expression of other genes associated with neurobehavioral abnormalities and/or neurodevelopmental disorders were found to be altered in this patient. These results suggest a likely contribution of RAI1, either alone or in combination of other factors, to social behavior and reinforce the <i>RAI1</i> gene as a candidate gene in patients with autistic manifestations or social behavioral abnormalities.
BibTeX
@inproceedings{abad2018rare,
  author = {Clemer Abad and Melissa M. Cook and Lei Cao and Julie R. Jones and Nalini R. Rao and Lynn Dukes‐Rimsky and Rini Pauly and Cindy Skinner and Yunsheng Wang and Feng Luo and R.E. Stevenson and Katherina Walz and Anand Srivastava},
  title = {{A Rare De Novo RAI1 Gene Mutation Affecting BDNF-Enhancer-Driven Transcription Activity Associated with Autism and Atypical Smith-Magenis Syndrome Presentation}},
  booktitle = {Biology},
  year = {2018},
  doi = {10.3390/biology7020031},
}
Figure